Boston, United States
Boston, United States

Time filter

Source Type

Patent
Schepens Eye Research Institute | Date: 2015-03-19

The disclosure features systems for providing information to a user about the users environment, the system featuring a detection apparatus configured to obtain image information about the environment, where the image information corresponds to information at multiple distances relative to a position of the user within the environment, and an electronic processor configured to obtain focal plane distance information defining a set of one or more distance values relative to the position of the user within the environment, construct one or more confocal images of the environment, from the image information and the set of one or more distance values, wherein each of the one or more confocal images corresponds to a different distance value and comprises a set of pixels, and transform the one or more confocal images to form one or more representative images comprising fewer pixels and a lower dynamic range.


Patent
Schepens Eye Research Institute | Date: 2015-07-17

Systems, apparatus, and methods are provided for quantifying inter-ocular suppression in binocular vision impairment. The systems, apparatus, and methods may include a stimulus presentation device and a controller which present different stimuli to each eye of a patient. The stimuli can include letters, numbers, or shapes which are arranged in rows, and columns with a stimulus presented to each eye in a location corresponding a stimulus presented to the other eye. The combined contrast of corresponding stimuli equals a predetermined value, and this contrast can be adjusted with each iteration of stimuli presented. This adjustment can be based upon the patients reports of what is seen and adjustments made by an algorithm executed by the controller. Suppression can thus be determined in terms of visual field location and quantified.


Patent
Schepens Eye Research Institute | Date: 2016-11-18

Systems, apparatus, and methods are provided for quantifying inter-ocular suppression in binocular vision impairment. The systems, apparatus, and methods may include a stimulus presentation device and a controller which present different stimuli to each eye of a patient. The stimuli can include letters, numbers, or shapes which are arranged in rows, and columns with a stimulus presented to each eye in a location corresponding a stimulus presented to the other eye. The combined contrast of corresponding stimuli equals a predetermined value, and this contrast can be adjusted with each iteration of stimuli presented. This adjustment can be based upon the patients reports of what is seen and adjustments made by an algorithm executed by the controller. Suppression can thus be determined in terms of visual field location and quantified.


Patent
Massachusetts Eye, Ear Infirmary and Schepens Eye Research Institute | Date: 2016-10-12

Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.


Patent
Schepens Eye Research Institute | Date: 2016-06-10

The invention provides compositions and methods for utilizing endomucin as an anti-inflammatory agent.


Joyce N.C.,Schepens Eye Research Institute
Experimental Eye Research | Year: 2012

The corneal endothelial monolayer helps maintain corneal transparency through its barrier and ionic "pump" functions. This transparency function can become compromised, resulting in a critical loss in endothelial cell density (ECD), corneal edema, bullous keratopathy, and loss of visual acuity. Although penetrating keratoplasty and various forms of endothelial keratoplasty are capable of restoring corneal clarity, they can also have complications requiring re-grafting or other treatments. With the increasing worldwide shortage of donor corneas to be used for keratoplasty, there is a greater need to find new therapies to restore corneal clarity that is lost due to endothelial dysfunction. As a result, researchers have been exploring alternative approaches that could result in the invivo induction of transient corneal endothelial cell division or the invitro expansion of healthy endothelial cells for corneal bioengineering as treatments to increase ECD and restore visual acuity. This review presents current information regarding the ability of human corneal endothelial cells (HCEC) to divide as a basis for the development of new therapies. Information will be presented on the positive and negative regulation of the cell cycle as background for the studies to be discussed. Results of studies exploring the proliferative capacity of HCEC will be presented and specific conditions that affect the ability of HCEC to divide will be discussed. Methods that have been tested to induce transient proliferation of HCEC will also be presented. This review will discuss the effect of donor age and endothelial topography on relative proliferative capacity of HCEC, as well as explore the role of nuclear oxidative DNA damage in decreasing the relative proliferative capacity of HCEC. Finally, potential new research directions will be discussed that could take advantage of and/or improve the proliferative capacity of these physiologically important cells in order to develop new treatments to restore corneal clarity. © 2011 Elsevier Ltd.


Patent
Schepens Eye Research Institute | Date: 2016-03-29

Described herein are materials and methods of treating dry eye disease in a subject.


Patent
The Regents Of The University Of California and Schepens Eye Research Institute | Date: 2016-04-06

The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.


Patent
Schepens Eye Research Institute | Date: 2016-03-07

The invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-17 and methods for using this composition to treat IL-17-mediated ocular inflammatory disorders. The invention also discloses devices for delivering this composition to the eye.


Patent
Massachusetts Eye, Ear Infirmary and Schepens Eye Research Institute | Date: 2016-04-11

Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.

Loading Schepens Eye Research Institute collaborators
Loading Schepens Eye Research Institute collaborators